The Telomeric DNA Damage Response As A Therapeutic Target In Idiopathic Pulmonary Fibrosis

Research indicates that a specific DNA damage response at the ends of chromosomes, known as the telomeric DNA damage response, is a direct cause of idiopathic pulmonary fibrosis, and inhibiting this response could be a promising treatment.

Our bodies have protective caps on the ends of our chromosomes, called telomeres, which are like the plastic tips on shoelaces, preventing fraying. As we age and our cells divide, these telomeres naturally shorten. When they become too short or damaged, they trigger a “DNA damage response,” a cellular alarm system designed to fix problems with our genetic material. In the context of these protective caps, this is called the telomeric DNA damage response.

Recent findings shed light on a severe lung disease called idiopathic pulmonary fibrosis (IPF), a condition where the lungs become scarred and stiff, making it progressively harder to breathe. This research suggests that the activation of this specific telomeric DNA damage response plays a direct and harmful role in the development of IPF. Essentially, when these protective caps at the ends of chromosomes become dysfunctional, they send out distress signals that contribute to the disease.

Crucially, the study explored a potential therapeutic approach: using special molecules called telomeric antisense-oligonucleotides (tASOs) to block this harmful telomeric DNA damage response. In models of IPF, treatment with these tASOs successfully reduced DNA damage, inflammation, and the scarring in the lungs. This indicates that by targeting and inhibiting this specific cellular response, it might be possible to develop new and effective treatments for IPF, offering hope for patients suffering from this debilitating condition.

---

Source: link to paper